These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 22364065)

  • 1. Managing chronic kidney disease in type 2 diabetes in family practice.
    Scott D; Davidson JA
    J Natl Med Assoc; 2011; 103(9-10):952-9. PubMed ID: 22364065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases.
    Bramlage P; Lanzinger S; van Mark G; Hess E; Fahrner S; Heyer CHJ; Friebe M; Seufert J; Danne T; Holl RW
    Cardiovasc Diabetol; 2019 Mar; 18(1):33. PubMed ID: 30878037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Population-Based Analysis of Quality Indicators in CKD.
    Manns L; Scott-Douglas N; Tonelli M; Weaver R; Tam-Tham H; Chong C; Hemmelgarn B
    Clin J Am Soc Nephrol; 2017 May; 12(5):727-733. PubMed ID: 28377473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on Diabetic Nephropathy: Core Curriculum 2018.
    Umanath K; Lewis JB
    Am J Kidney Dis; 2018 Jun; 71(6):884-895. PubMed ID: 29398179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist.
    Martínez-Ramírez HR; Jalomo-Martínez B; Cortés-Sanabria L; Rojas-Campos E; Barragán G; Alfaro G; Cueto-Manzano AM
    Am J Kidney Dis; 2006 Jan; 47(1):78-87. PubMed ID: 16377388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pattern and predictors of urine protein excretion among patients with type 2 diabetes attending a single tertiary hospital in Lagos, Nigeria.
    Bello BT; Amira CO
    Saudi J Kidney Dis Transpl; 2017; 28(6):1381-1388. PubMed ID: 29265051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of hypertension and its complications: theoretical basis and guidelines for treatment.
    Flack JM; Peters R; Shafi T; Alrefai H; Nasser SA; Crook E
    J Am Soc Nephrol; 2003 Jul; 14(7 Suppl 2):S92-8. PubMed ID: 12819310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment - systematic review and modelling of progression and cost-effectiveness.
    Farmer AJ; Stevens R; Hirst J; Lung T; Oke J; Clarke P; Glasziou P; Neil A; Dunger D; M Colhoun H; Pugh C; Wong G; Perera R; Shine B
    Health Technol Assess; 2014 Feb; 18(14):1-128. PubMed ID: 24576414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetic nephropathy--the family physician's role.
    Roett MA; Liegl S; Jabbarpour Y
    Am Fam Physician; 2012 May; 85(9):883-9. PubMed ID: 22612183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
    Sternlicht H; Bakris GL
    Blood Purif; 2016; 41(1-3):139-43. PubMed ID: 26766168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
    Mavrakanas TA; Gariani K; Martin PY
    Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual renin-angiotensin system blockade for nephroprotection.
    Ruggenenti P
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S43-S45. PubMed ID: 28577742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of chronic kidney disease and its risk factors among family practice patients in Lithuania.
    Bumblyte IA; Zilinskiene A; Vanholder R; Valius L; Kuzminskis V
    Clin Nephrol; 2012 Sep; 78(3):198-206. PubMed ID: 22874108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
    Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E;
    Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial.
    Barnett A
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S132-5. PubMed ID: 16565237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective review of diabetic nephropathy patients during referral to the sub-urban nephrology clinic.
    Menon R; Mohd Noor FS; Draman CR; Seman MR; Ghani AS
    Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):1109-14. PubMed ID: 22982937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
    Barnett AH; Bain SC; Bouter P; Karlberg B; Madsbad S; Jervell J; Mustonen J;
    N Engl J Med; 2004 Nov; 351(19):1952-61. PubMed ID: 15516696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.